Badanie skuteczności i bezpieczeństwa Ravulizumabu u dzieci i młodzieży z Neuromyelitis Optica Spectrum Disorder (NMOSD)

Neuromyelitis Optica Spectrum Disorder (NMOSD) is a rare condition that affects the nervous system, particularly the optic nerves and spinal cord. This study focuses on evaluating the effectiveness and safety of a medication called ravulizumab in children and adolescents with NMOSD. Ravulizumab is given as an infusion, which means it is administered directly into the bloodstream through a vein.

The purpose of the study is to assess how well ravulizumab works in reducing the frequency of relapses in young patients with NMOSD. Participants in the study will receive ravulizumab and will be monitored over time to see how the treatment affects their condition. The study will also look at the safety of the medication, checking for any side effects or changes in health indicators like weight, height, and laboratory test results.

Throughout the study, participants will have regular check-ups to track their progress and any changes in their symptoms. The study aims to provide valuable information on the use of ravulizumab in managing NMOSD in a younger population, potentially offering a new treatment option for this challenging condition.